To improve targeted cargo delivery to cancer cells, pH-Low
Insertion
Peptide (pHLIP) variants were developed to interact with the membrane
at pH values higher than those of the WT. The Asp-to-Glu variants
aim to increase side chain pK
a without
disturbing the sequence of protonations that underpin membrane insertion.
The Thr19 variants represent efforts to perturb the critical Pro20
residue. To study the effect of cargo on pHLIP insertion, doxorubicin
(Dox), a fluorescent antineoplastic drug, was conjugated to selected
variants near the inserting C-terminus. Variants and conjugates were
characterized on a POPC membrane using Trp and Dox fluorescence methods
to define the entire pH range of insertion (pHinitial–pHfinal). Compared to WT with a pHi–pHf range of 6.7–5.6, D25E-D31E-D33E, D14E-D25E-D31E-D33E,
and T19V-D25E variants demonstrated higher pHi–pHf ranges of 7.3–6.1, 7.3–6.3, and 8.2–5.4,
respectively. The addition of Dox expanded the pHi–pHf range, mainly by shifting pHi to higher pH values
(e.g., WT pHLIP-Dox has a pHi–pHf range
of 7.7–5.2). Despite the low Hill coefficient observed for
the conjugates, D14E-D25E-D31E-D33E pHLIP-Dox completed insertion
by a pHf of 5.7. However, the Dox cargo remained in the
hydrophobic membrane interior after pHLIP insertion, which may impede
drug release. Finally, a logistic function can describe pHLIP insertion
as a peripheral-to-TM (start-to-finish) two-state transition; wherever
possible, we discuss data deviating from such sigmoidal fitting in
support of the idea that pH-specific intermediate states distinct
from the initial peripheral state and the final TM state exist at
intervening pH values.